“Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India. Together, these new initiatives bring differentiated therapies and meaningful innovation closer to the patients,” said Kirti Ganorkar, Managing Director, Sun Pharma.
The company’s Board has declared an interim dividend of Rs. 11.00 per share for FY26 against Rs 10.50 per share interim dividend for the previous year.
Formulation sales in the US were $477 million, marginally up by 0.6%. The company’s innovative medicines business continued to grow in the US, offsetting the decline in generics business. US sales accounted for approximately 27.5% of total consolidated sales. For the first nine months, sales were $1,445 million.
Its global innovative medicines sales stood at $423 million for Q3FY26. This included a milestone income of $55 million. Ex-milestone, global innovative medicines sales were up 13.2% and accounted for 21.2% of sales. For the first nine months, sales were $1,067 million, up by 15.7% over the same period last year.
Formulation sales in India were Rs 49,98.60 crore, up 16.2%. India Formulation sales accounted for 32.3% of total consolidated sales.
Sun’s innovative R&D pipeline includes five novel entities in the clinical stage. It has a comprehensive product offering in the US market consisting of approved ANDAs for 550 products, while filings for 116 ANDAs await US FDA approval, including 28 tentative approvals. During the quarter, 2 ANDAs were filed, and approval was received for 2 ANDAs. Sun’s portfolio includes 57 approved NDAs, while 14 NDAs await US FDA approval. End
